Faron Pharmaceuticals Oy (LSE:FARN) EPS (Basic): £-0.19 (TTM As of Dec. 2025)


LSE:FARN Faron Pharmaceuticals Oy LSE:FARN
22 GF Score
Price £0.44
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy EPS (Basic)?

Faron Pharmaceuticals Oy LSE:FARN 22 EPS (Basic) is £-0.19 as of Dec. 2025. GuruFocus rates LSE:FARN with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

Faron Pharmaceuticals Oy's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was £-0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.19.

Faron Pharmaceuticals Oy's EPS (Diluted) for the six months ended in Dec. 2025 was £-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.19.

Faron Pharmaceuticals Oy's EPS without NRI for the six months ended in Dec. 2025 was £-0.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.19.

During the past 3 years, the average EPS without NRI Growth Rate was 19.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Faron Pharmaceuticals Oy's highest 3-Year average EPS without NRI Growth Rate was 19.70% per year. The lowest was -139.60% per year. And the median was -14.10% per year.

Faron Pharmaceuticals Oy  (LSE:FARN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Faron Pharmaceuticals Oy EPS (Basic) Related Terms

Faron Pharmaceuticals Oy EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy EPS (Basic) Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 -0.35 -0.38 -0.22 -0.19

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.16 -0.07 -0.14 -0.05
LSE:FARN
22GF Score
Faron Pharmaceuticals Oy LSE:FARN
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Faron Pharmaceuticals Oy's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-23.842-0)/121.471
=-0.20

Faron Pharmaceuticals Oy's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.852-0)/126.162
=-0.05

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of £-0.19 mean?
Faron Pharmaceuticals Oy (LSE:FARN) has a EPS (Basic) of £-0.19 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's EPS (Basic) too high?
Faron Pharmaceuticals Oy's current EPS (Basic) is £-0.19. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's EPS (Basic) compare to VRTX and REGN?
Faron Pharmaceuticals Oy's EPS (Basic) of £-0.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current EPS (Basic) is £-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (LSE:FARN) has a current EPS (Basic) of £-0.19. The current EPS (Basic) is £-0.19. Faron Pharmaceuticals Oy's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (LSE:FARN), the current EPS (Basic) is £-0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARON:Finland4FR:Germany
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
22GF Score

Get the complete analysis for LSE:FARN

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.44
Price